Taken together, oncogenic mutations of MYD88 and CD79B in DLBCL have major implications for clinical practice (Visco et al., 2020) and may provide useful genetic tools for personalized targeted therapies. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.